Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms

Table 5 Pre-treatment and post-treatment inflammatory indices and immunophenotyping in patients (n = 76), mean ± SD

Parameter	Pre-treatment	Post-treatment	P value
SII	30971.8 ± 14428.6	1500.0 ± 800.0	< 0.001b
SIRI	250.7 ± 200.2	5.0 ± 2.5	< 0.001b
PD-L1/CXCR3 (%)	51.10 ± 16.77	43.31 ± 24.45	0.011a
PD-1/CXCR3 (%)	12.28 ± 1.46	12.75 ± 7.57	0.366
CXCR3/T lymphocytes (%)	52.03 ± 9.40	12.75 ± 7.57	< 0.001b
CXCR3/classical monocytes (%)	14.57 ± 5.78	13.50 ± 5.50	0.052
CXCR3/intermediate monocytes (%)	20.56 ± 7.31	19.00 ± 6.50	0.068
CXCR3/non-classical monocytes (%)	15.0 ± 7.20	14.00 ± 6.00	0.075

^aP < 0.05.

^bP < 0.001.

SII: Systemic immune-inflammation index; SIRI: Systemic inflammation response index; PD-L1: Programmed death-ligand 1; CXCR3: C-X-C motif chemokine receptor 3; PD-1: Programmed cell death protein 1.